Directors

Carl W. Hull
Chairman of the Board
Chief Executive Officer
BA, (Political Science and International Relations) The Johns Hopkins University;
MBA, University of Chicago

Mr. Hull joined the Company in February 2007 as Executive Vice President and Chief Operating Officer. He was promoted to President in February 2008, Chief Executive Officer in May 2009 and Chairman of the Board and Chief Executive Officer in January 2012. Mr. Hull previously served as Vice President & General Manager of the SDS/Arrays Business Unit of Applied Biosystems, which develops and sells genomic research systems and reagents, from January 2005 to January 2007. Prior to joining Applied Biosystems, Mr. Hull held a number of positions with Applied Imaging Corp., which makes automated imaging and imaging analysis systems, most recently serving as its Chief Executive Officer from January 2001 to December 2004. Mr. Hull received a B.A. in political science and international relations from The Johns Hopkins University and an M.B.A. from the University of Chicago.

Robert B. Blake
Vice President, Research and Development
BS and MS in Electrical/Computer Engineering and Robots from Brown University

Mr. Blake joined the Company in October 2006 as Vice President, Instrument Systems. Mr. Blake has over twenty years of experience in instrument development. Prior to joining the Company, Mr. Blake worked as a Director of System Development in the Diagnostics Division of Bayer Corporation, a subsidiary of Bayer AG, a global health care, nutrition and innovative materials company, from March 2003 until October 2006, contributing to the Centaur CP, Centaur XP and Versant 440 projects. Prior to his employment with Bayer, Mr. Blake worked from June 2002 to March 2003 as a consultant for NPE Systems, Inc., a life sciences company. From January 2001 until June 2002, Mr. Blake served as Vice President, Product Development & Manufacturing for Varacel Corporation. Mr. Blake received a B.S. and M.S. in Electrical/Computer Engineering and Robots from Brown University.

Michael H. Berrendorf
Vice President, Europe
Engineer & MBA, Technical University of Berlin

Mr. Berrendorf joined the Company in March 2009 as Managing Director EMEA. He was promoted to Vice President Europe for Clinical Diagnostics and Life Sciences in April 2010. Mr. Berrendorf previously served as Director Sales EMEA at BodyTel Europe GmbH, which develops and sells telemedicine products specialized in Diabetes Care and Cardiovascular, from September 2007 to February 2009. Prior to joining BodyTel, from January 2003 to August 2007, Mr. Berrendorf held the position of Vice President Sales & Service EMEA & General Manager Germany with Thermo Fisher Scientific, which make analytical instruments, laboratory equipment, software, consumables and reagents. From April 1981 to December 2002, Mr. Berrendorf held a number of management positions in Sales, Marketing, Service and General Management with ABBOTT Laboratories, Diagnostics Division, which develops and markets diagnostic instrumentation and reagents.

R. William Bowen
Senior Vice President, General Counsel & Secretary
BS, (Commerce) University of Virginia School of Commerce; JD, University of Virginia School of Law

Mr. Bowen joined the Company in 1997 as Vice President, General Counsel and Assistant Secretary and was appointed Secretary in August 2002. Prior to joining the Company, he was a business litigation partner with the law firm of Luce, Forward, Hamilton & Scripps in San Diego, California. He received a B.S. in commerce and a J.D. from the University of Virginia.

Tammy J. Brach
Vice President, Program Management
BS, (Industrial Engineering) Texas A&M; MBA, Drake University

Ms. Brach joined the Company in September 2007. Ms. Brach previously served as Program Director of the Applied Markets Business Unit of Applied Biosystems, which develops and sells Forensic, Biosecurity, and Quality Food Safety Testing products from March 2005 to August 2007. Prior to joining Applied Biosystems, Ms. Brach was a Program Management Director for Fisher Diagnostics, managing alliance programs as well as supply chain from July 2003 to March 2005. Ms. Brach received a B.S. in Industrial Engineering from The Texas A&M and an M.B.A. from Drake University.

Ingo Chakravarty
Vice President and General Manager, Women’s Health
AD, Electrical Engineering, Friedrich Haecker Schule (Germany)

Mr. Chakravarty joined Gen-Probe in March of 2011 to lead a new business unit focused on the strategy and commercial success of the Company’s women’s health franchise. Prior to joining the Company, he held several leadership positions at Roche Tissue Diagnostics (formerly Ventana Medical Systems), working in both Europe and the United States. Most recently Mr. Chakravarty was the Head of Sales for Roche’s European Tissue Diagnostics business. Before that, he was responsible for strategic marketing, product and business development for Ventana’s Imaging Solutions division, and ran Ventana’s Advanced Staining Platforms group.

Diana De Walt
Senior Vice President, Human Resources

Ms. De Walt joined the Company in January 2005. Prior to joining the Company, Ms. De Walt founded The HR Company in 1993 and served as its President and Principal Consultant providing professional human resources services to over 85 companies in a wide variety of industries. From 1988 to 1993, Ms. De Walt worked at Mitek Systems, Inc. as Director, Human Resources and subsequently Vice President, Human Resources. From 1987 to 1988, Ms. De Walt was Vice President, Human Resources of Imperial Savings Real Estate Lending Group. From 1984 to 1987, Ms. De Walt was Manager, Human Resources of Security Pacific Business Credit and Vice President, Human Resources of Security Pacific Business Finance. Ms. De Walt received an A.A. in liberal arts from St. Cloud State University and holds a Senior Professional In Resource Management certification.

Jorgine Ellerbrock
Senior Vice President, Operations
BS, (Microbiology) San Diego State University; MBA, San Diego State University

Ms. Ellerbrock joined the Company in November 2007. She previously served as Vice President, Operations at Invitrogen Corporation from August 2004 to November 2007, most recently for the Molecular Biology Business. Prior to joining Invitrogen, she held positions of increasing responsibility with GE Healthcare Bio-Sciences (formerly Amersham Biosciences). She served as Vice President, Operations from 2002 to 2004, and Vice President, Genomics Product Management, in 2002. Before joining Amersham in 1998, Ms. Ellerbrock was employed by Roche Molecular Systems and Gen-Probe. Ms. Ellerbrock received a B.S. in Microbiology and an M.B.A., both from San Diego State University.

Cristina Giachetti
Ph.D., Vice President, Research and Development
Ph.D., (Biochemistry) University of Buenos Aires

Dr. Giachetti joined the Company in 1995 to lead the technical team that developed the first FDA licensed blood-screening test for simultaneous detection of HIV-1 and HCV nucleic acids. From then she went on to hold positions of increased responsibility in the area of Blood Screening Products and her work directly contributed to the National Medal for Technology that Gen-Probe received in 2006. After her promotion to Senior Director, Product Development in 2004, her responsibilities extended to the area of Diagnostics. Prior to joining Gen-Probe, Dr. Giachetti worked as staff scientist at Genta and prior to that she performed basic research in virology, molecular virology and rapid viral evolution at UCSD and UCI. Dr. Giachetti has authored over 40 peer review publications and has made multiple presentations at national and international scientific meetings. She received her degrees in Clinical Analysis and Biochemistry from the School of Pharmacy and Biochemistry of the University of Buenos Aires and a Ph.D. in Biochemistry from the same University. She completed postdoctoral training at the University of California, San Diego, Department of Biology and at the University of California, Irvine, Department of Microbiology and Molecular Genetics.

Brian B. Hansen
Vice President, Americas and Asia Pacific
BS, (Business Administration) University of Missouri, Columbia, MO; MBA, San Diego State University, San Diego, CA

Mr. Hansen joined Gen-Probe in December 2005 as Sr. Director, Domestic Sales. Prior to Gen-Probe, Mr. Hansen was with Fisher Scientific as Vice President of Sales for the Healthcare Division from June 2004 to December 2005 and the Diagnostic Division from August 2003 to June 2004. From October 2001 to August 2003, Mr. Hansen was with PSS World Medical, a distributor of physician office supplies, as Vice President of Sales. From June 1999 to July 2001, Mr. Hansen was Director of Sales for Avocet Medical, a life sciences company. He has also held sales and marketing positions at Spacelabs-Burdick and Quidel. Mr. Hansen received his BSBA from The University of Missouri in 1989 and his MBA from San Diego State University in 1992.

Kevin Herde
Vice President, Finance, and Corporate Controller
BBA, University of San Diego (Business Administration); CPA

Mr. Herde joined the Company in April 2002 and has served as Director of Internal Audit, Director of Financial Planning and Analysis, and Senior Director, Finance, and Corporate Controller. Prior to joining the Company, he was with Gateway, the global computer manufacturer and retailer, from 2000 to 2002. Prior to that, Mr. Herde worked for KPMG at various levels, ultimately as an Audit Manager for public companies. He earned a B.B.A. in business administration from the University of San Diego and is a Certified Public Accountant (CPA).

Daniel L. Kacian
Ph.D., M.D., Executive Vice President and Chief Scientist
BA, (Mathematics) Western Reserve University; MS, (Microbiology) and Ph.D. (Molecular Genetics) University of Illinois; MD, University of Miami

Dr. Kacian joined the Company in 1985 as Director of Medical and Scientific Affairs and until 1992 was primarily responsible for directing Research & Development and Regulatory Affairs. Dr. Kacian held various management positions with the Company and, in 2002, was promoted to Executive Vice President and Chief Scientist. From 1980 to 1985, Dr. Kacian was on the faculty of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania and was Director of Clinical Microbiology at the Hospital of the University of Pennsylvania. He received an M.D. in 1978 from the University of Miami and did his internship and residency in laboratory medicine at Washington University and Barnes Hospital in St. Louis. Prior to attending medical school, Dr. Kacian received a B.A. in mathematics from Western Reserve University and an M.S. in microbiology and Ph.D. in molecular genetics from the University of Illinois and served on the faculty of the Department of Human Genetics and Development at Columbia University.

Tadd Lazarus
Vice President, Clinical Affairs and Chief Medical Officer
BS, Marlboro College; MD, Ross University School of Medicine; Internal Medicine Residency Program, Englewood Hospital

Dr. Lazarus joined the company in September 2010. He previously served as Medical Director of Roche Diagnostics Corporation (U.S.) for 12 years. Dr. Lazarus practiced Internal Medicine with a concentration in HIV Primary Care for 20 years. Prior to joining Roche Dr. Lazarus was the Director of HIV Ambulatory Care Program at the former St. Vincent's Hospital and Medical Center of New York City. Dr. Lazarus is the Vice-Chair of the Infectious Disease Committee of the Medical Society of the State of New York.

Brad Phillips
Vice President and Chief Information Officer
BS, Rose-Hulman Institute of Technology (Computer Science)

Mr. Phillips joined the Company in October 2008. He previously served as Vice President, Information Technology, for Favrille, where he was responsible for general information technology requirements as well as implementing electronic batch records for biologics manufacturing. Prior to joining Favrille, Mr. Phillips was Vice President of Information Technology at ChemNavigator, a cheminformatics systems and services provider. Mr. Phillips earned his B.S. in Computer Science from Rose-Hulman Institute of Technology.

Herm Rosenman
Senior Vice President, Finance and Chief Financial Officer
BBA, (Finance and Accounting) Pace College (now Pace University); MBA (Finance) The Wharton School of the University of Pennsylvania; CPA

Mr. Rosenman joined the Company as Chief Financial Officer in June 2001. Prior to joining the Company, he was President and Chief Executive Officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, from 1997 to 2000. He was President and Chief Executive Officer of RadNet Management, Inc., a large healthcare provider, from 1994 to 1997, and prior to that was Chief Financial Officer of Rexene Corp., a Fortune 1000 company in the petrochemicals industry. Mr. Rosenman was previously a partner at Coopers & Lybrand (now PricewaterhouseCoopers LLP) where he served numerous Fortune 1000 clients, principally in the pharmaceuticals and telecommunications industries. He received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania. Mr. Rosenman serves on the Board of Directors of ARYx Therapeutics, a publicly-owned drug discovery and development company, where he serves as Chairman of the Audit Committee and as Lead Independent Director.

Eric Tardif
Senior Vice President, Corporate Development and Marketing
BA (Business) Bishop's University; MBA University of British Columbia; MSF Boston College; CFA

Mr. Tardif joined the Company as Senior Vice President, Corporate Strategy in 2009. He added responsibility for Marketing in 2010 and Business Development in 2011. Prior to Gen-Probe, Mr. Tardif was a managing director in Morgan Stanley's healthcare investment banking group, focused on providing strategic and financial advisory services to diagnostics, life sciences tools and medical technology companies. Before joining Morgan Stanley in 2006, Mr. Tardif was an investment banker with Piper Jaffray from 2003 to 2006, and with Merrill Lynch from 1999 to 2003. He received his BA from Bishop's University in Québec, his MBA from the University of British Columbia, and his Master of Science in Finance from the Boston College Carroll Graduate School of Management. Mr. Tardif holds a chartered financial analyst (CFA) designation.

Michael Watts
Vice President, LIFECODES and Prodesse
BS, Medill School of Journalism at Northwestern University; MBA, the Anderson School at UCLA

Mr. Watts joined Gen-Probe in November of 2003 as Senior Director of Investor Relations and Corporate Communications. He added responsibility for Community Relations in 2004, Government Affairs in 2007, and Library Services in 2008. Before joining the Company, he was Director of Investor Relations and Corporate Communications at Ligand Pharmaceuticals, and Director of Strategy for Baxter BioScience. He also spent seven years at Merck & Co., Inc. in a variety of corporate communications, marketing support, public affairs and sales roles.

Christina Yang
Senior Vice President, Regulatory & Quality
BS, (Biology) National Taiwan Normal University; Ph.D., (Zoology) Iowa State University

Dr. Yang joined the Company in April 2007 as Vice President, Clinical, Regulatory and Quality. Dr. Yang brings over fifteen years experience in regulatory and clinical affairs, quality assurance and quality control. Most recently, Dr. Yang served as Vice President, Quality and Regulatory Affairs of Focus Diagnostics, owned by Quest Diagnostics, consisting of laboratory services, clinical trial and IVD production units with focus on infectious disease. Immediately prior, Dr. Yang held a variety of management positions in R&D, quality systems, diagnostic operations, and technical manufacturing. From 1987 to 1995, Dr. Yang served in quality control, biochemistry and allergy, and organic chemistry management positions at Diagnostic Products Corporation in Los Angeles. She has a B.S. in Biology from National Taiwan Normal University, Taipei, Taiwan and a Ph.D in Zoology from Iowa State University, Iowa. Dr. Yang is a Regulatory Affairs Certified (RAC), ISO9000 certified lead auditor as well as a Certified Quality Auditor (CQA).

Patrick J. Sullivan

Mr. Sullivan has served as a director of the Company since September 2010. He is the former chairman, president and chief executive officer of Cytyc Corporation, a leading women's health company that merged with Hologic in 2007. Mr. Sullivan joined Cytyc in 1991 as vice president, sales and marketing. He became president, CEO and a director in 1994, and added the chairman's title in 2002. Mr. Sullivan now leads Constitution Medical Investors, a Boston-based private investment firm in partnership with Warburg Pincus, and is also a director of PerkinElmer. He graduated with distinction from the U.S. Naval Academy and earned an M.B.A., also with distinction, from Harvard University.

Henry L. Nordhoff

Mr. Nordhoff has served as a director of the Company since July 1994. Mr. Nordhoff joined the Company in July 1994 as Chief Executive Officer and President and was elected Chairman of the Board in September 2002. Mr. Nordhoff retired as the Company's Chief Executive Officer on May 17, 2009. Prior to joining the Company, Mr. Nordhoff was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. Prior to that, Mr. Nordhoff was at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. Mr. Nordhoff received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University. Mr. Nordhoff has also served as a member of the board of directors of MannKind Corporation since March 2005. The Board believes that Mr. Nordhoff's formal education, international business success and demonstrated leadership, including while serving as Chairman of the Board and as the Company's former CEO for 15 years during which the Company experienced significant growth, provide Mr. Nordhoff with the appropriate attributes to lead the Company's Board of Directors and enable him to make valuable contributions to the Board and to the Company.

John W. Brown

Mr. Brown has served as a director of the Company since December 2005. Mr. Brown previously served as President and Chief Executive Officer of Stryker Corporation, a worldwide leader in orthopedic medical devices, from 1997 until 2004, and Chairman of the Board of Stryker Corporation from 1980 through 2009. Mr. Brown currently serves as Chairman Emeritus of Stryker Corporation. Mr. Brown has also served as a director of St. Jude Medical, Inc. since August 2005. Mr. Brown received a bachelor's degree in chemical engineering from Auburn University. The Board believes Mr. Brown's formal education and success throughout his career, including his over 25-year tenure as the Chairman and CEO of Stryker Corporation, a Fortune 400 company and member of the S&P 500 that achieved this status under Mr. Brown's leadership, provide Mr. Brown with the appropriate attributes to serve on the Board and enable him to make valuable contributions to the Board and to the Company.

Carl W. Hull
Chairman of the Board
Chief Executive Officer

Mr. Hull has served as a director of the Company since May 2009. Mr. Hull joined the Company in February 2007 as Executive Vice President and Chief Operating Officer and was appointed President in February 2008. Mr. Hull was appointed as the Company's Chief Executive Officer ("CEO") and elected as a director in May 2009 and Chairman of the Board and Chief Executive Officer in January 2012. Prior to joining the Company, Mr. Hull served as Vice President & General Manager of the SDS/Arrays Business Unit of Applied Biosystems Inc. from January 2005 to January 2007. Prior to joining Applied Biosystems, Mr. Hull held a number of positions with Applied Imaging Corp., most recently serving as its Chief Executive Officer from January 2001 to December 2004. Mr. Hull was a member of the board of directors of Applied Imaging Corp. from 2000 to 2007. Mr. Hull received a B.A. in political science and international relations from Johns Hopkins University and an M.B.A. from the University of Chicago. The Board believes that Mr. Hull's formal education, his position as President and CEO of the Company, his in-depth knowledge of the Company's businesses and industry, and his demonstrated leadership over the course of his successful career provide Mr. Hull with the appropriate attributes to serve on the Board and enable him to make valuable contributions to the Board and to the Company.

Armin M. Kessler

Mr. Kessler has served as a director of the Company since November 2002. Mr. Kessler served as Chief Operating Officer of Hoffman-La Roche in Basel, Switzerland from 1990 to 1995. Prior to being appointed Chief Operating Officer, Mr. Kessler held several senior positions at Hoffman-La Roche, including head of the diagnostics and pharmaceutical divisions of the organization. Earlier positions in his career included Director of Pharmaceutical Marketing Worldwide for Novartis AG (formerly Sandoz Ltd.) and President of Sandoz KK in Tokyo. Mr. Kessler currently serves on the board of directors of two other public companies, Actelion Pharmaceuticals Ltd., a Swiss publicly traded company, and The Medicines Company, and one private company, MedGenesis Therapeutix. Mr. Kessler has also served on the boards of Hoffman-La Roche, Syntex Chemicals Inc., PRA International, Inc., Spectrum Pharmaceuticals, Inc., Genentech, Inc. and CroMedica International, Inc. Mr. Kessler received a degree in physics and chemistry from Pretoria University in South Africa, a degree in chemical engineering from the University of Cape Town, South Africa, a J.D. from Seton Hall University, and a Dr.h.c. in business administration from the University of Pretoria. The Board believes that Mr. Kessler’s formal education, international business success and demonstrated leadership, including while serving as the former Chief Operating Officer of Hoffman-La Roche, and his current and former participation on numerous public company boards of directors provide Mr. Kessler with the appropriate attributes to serve on the Board and enable him to make valuable contributions to the Board and to the Company.

John C. Martin, Ph.D.

Dr. Martin has served as a director of the Company since September 2007. Dr. Martin has served as Chairman of the board of directors of Gilead Sciences, Inc. since May 2008, and has served as President and Chief Executive Officer and as a member of Gilead's board of directors since 1996. Prior to joining Gilead in 1990, Dr. Martin held several leadership positions in the antiviral chemistry division at Bristol-Myers Squibb Company and served for six years with Syntex Corporation, from 1978 until 1984. Dr. Martin is a member of the Presidential Advisory Council on HIV/AIDS and the board of directors of the California Healthcare Institute. Dr. Martin received a Ph.D. in organic chemistry from the University of Chicago and an M.B.A. in marketing from Golden Gate University. The Board believes Dr. Martin's formal education, scientific expertise, business success, including his tenure as Chairman and CEO of Gilead Sciences, a Fortune 500 company and member of the S&P 500 that achieved this status under Dr. Martin's leadership, provide Dr. Martin with the appropriate attributes to serve on the Board and enable him to make valuable contributions to the Board and to the Company.

Brian A. McNamee, MBBS

Dr. McNamee has served as a director of the Company since March 2010. Dr. McNamee previously served on the Company's Board of Directors from the time of its September 2002 spin-off from Chugai Pharmaceutical Co., Ltd. until May 2007. Dr. McNamee has served as the Chief Executive Officer and Managing Director of CSL Ltd. since 1990. CSL is a leading international biopharmaceutical company with significant activities in human plasma and vaccines. Prior to joining CSL, Dr. McNamee was Managing Director of a start-up biotechnology company, Pacific Biotechnology Limited, in Sydney, Australia and General Manager of Faulding Product Divisions, F.H. Faulding & Co Limited in Adelaide, Australia. Dr. McNamee obtained his medical degree from the University of Melbourne. The Board believes that Dr. McNamee's formal education, medical expertise, international business success, including while serving as the Chief Executive Officer and Managing Director of CSL, as well as his prior service on the Board provide Dr. McNamee with the appropriate attributes to serve on the Board and enable him to make valuable contributions to the Board and to the Company.

Phillip M. Schneider

Mr. Schneider has served as a director of the Company since November 2002. Mr. Schneider is the former Chief Financial Officer of IDEC Pharmaceuticals Corporation (now Biogen IDEC Inc.). During his 15-year tenure at IDEC, Mr. Schneider served as Senior Vice President and Chief Financial Officer where he played an integral role in the company's growth. Prior to his association with IDEC, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation and was previously with KPMG, LLP. Mr. Schneider is a member of the board of directors of Arena Pharmaceuticals, Inc. and Targegen, Inc., a privately held company. Mr. Schneider previously served on the board of directors of CancerVax Corporation from September 2003 until its merger with Micromet AG in May 2006, and, subsequently, Mr. Schneider served on the board of directors of the combined company, Micromet, Inc., until November 2007. Mr. Schneider received an M.B.A. from the University of Southern California and a B.S. in biochemistry from the University of California at Davis. The Board believes Mr. Schneider's formal education, financial and accounting expertise, business success, including while serving as the former Chief Financial Officer of IDEC, and his current and former membership on other public company boards of directors provide Mr. Schneider with the appropriate attributes to serve on the Board and enable him to make valuable contributions to the Board and to the Company.

Lucy Shapiro, Ph.D.

Dr. Shapiro has served as a director of the Company since May 2008. Dr. Shapiro currently serves as the Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University's School of Medicine, where she has served as a faculty member since 1989. Dr. Shapiro is a co-founder and director of Anacor Pharmaceuticals, a privately held biopharmaceutical company developing novel small-molecule therapeutics to treat infectious and inflammatory diseases. From 1989 to 1997, Dr. Shapiro was the founding Chair of Stanford University's Department of Developmental Biology. From 1986 to 1989, Dr. Shapiro served as Chair of the Department of Microbiology in the College of Physicians and Surgeons of Columbia University, where she also served as a faculty member. Dr. Shapiro has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. Dr. Shapiro was elected to the American Philosophical Society and received the Selman A. Waksman Award from the National Academy of Sciences in 2005, the Canada Gairdner International Award in 2009, the John Scott Award in 2009 and the Abbott-ASM Lifetime Achievement Award in 2010. Dr. Shapiro previously served as a non-executive director of GlaxoSmithKline plc from 2001 to 2006. Dr. Shapiro received a B.A. from Brooklyn College and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine. The Board believes Dr. Shapiro's formal education, significant expertise in the biotechnology industry, professional accomplishments and her former membership on the board of directors of GlaxoSmithKline provide Dr. Shapiro with the appropriate attributes to serve on the Board and enable her to make valuable contributions to the Board and to the Company.

The Honorable Abraham D. Sofaer

Mr. Sofaer has served as a director of the Company since August 2002. Since 1994, Mr. Sofaer has been the George P. Shultz Distinguished Scholar and Senior Fellow, The Hoover Institution, Stanford University. Mr. Sofaer previously served as a United States District Judge for the Southern District of New York, as the Legal Adviser for the United States Department of State, as a Professor at Columbia University School of Law, and as a partner in the New York law firm of Hughes, Hubbard & Reed. Mr. Sofaer is a member of the board of directors of one other public company, Rambus, Inc., and three private companies, 3L&T, Inc., IntelliGeneScan, Inc. and PLC Diagnostics Inc. Mr. Sofaer previously served on the board of directors of Neurobiological Technologies, Inc. from April 1997 to November 2009. Mr. Sofaer received a B.A. in history from Yeshiva College and an L.L.B. from New York University School of Law. Mr. Sofaer has had extensive litigation experience, as a federal prosecutor, judge, private lawyer, and currently as an arbitrator serving under the rules of several arbitration companies. Mr. Sofaer's charitable activities include service for many years as Chairman and now Vice-Chairman of the board of directors of the National Jazz Museum in Harlem, and on the board of directors of the Koret Foundation, where he is also Chairman of the Audit Committee. The Board believes Mr. Sofaer's formal education, legal expertise, judicial experience, demonstrated professional success in the business and academic sectors, and his current and former membership on other public company boards of directors provide Mr. Sofaer with the appropriate attributes to serve on the Board and enable him to make valuable contributions to the Board and to the Company.